- €13.00bn
- €12.43bn
- €3.93bn
Brief: Ipsen Raises FY 2024 Guidance
Brief: Ipsen H1 Adjusted EPS EUR 4.78
Brief: Ipsen, Foreseen Biotechnology Enter Licensing Agreement For Antibody-Drug Conjugate
Europe Research Roundup: Pearson, Softcat, Trelleborg
Brief: Ipsen To Seek Marketing Authorizations For Cabometyx Outside Of U.S., Japan
Brief: Ipsen’S Iqirvo® Receives U.S. FDA Accelerated Approval As A First-In-Class Ppar Treatment For Primary Biliary Cholangitis
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug (updated)
US FDA approves Genfit and Ipsen's liver disease drug
Brief: Ipsen Initiates Share Buy-Back Program
Brief: Genfit Q1 Revenue Falls to EUR 1.1 Million
Europe Research Roundup: Alfa Laval, OMV AG, Unilever Plc
Europe Research Roundup: Adidas, EFG International, Smith & Nephew
Brief: Ipsen Appoints Keira Driansky As EVP, President Of North America
Europe Research Roundup: Barclays, JD Sports, Renault
Ipsen rises after cancer treatment drives Q1 beat
Brief: Ipsen Q1 Revenue EUR 822.4 Million
Brief: Ipsen Confirms Financial Guidance For 2024
French and Benelux stocks-Factors to watch
Brief: Ipsen, Skyhawk Therapeutics Announce RNA Targeting Research Collaboration In Rare Neurological Diseases